• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom names Jake Leach chief operating officer

September 1, 2022 By Sean Whooley

Jake Leach Dexcom COO
Dexcom COO Jake Leach

Dexcom (Nasdaq:DXCM) announced that it promoted chief technology officer Jake Leach to the chief operating officer (COO) role.

Leach served as CTO since 2018, leading the company’s research, product development, product management and engineering departments. He joined the company in 2004 to lead the development of sensor electronics for its first commercial continuous glucose monitor (CGM) system.

In the 18 years Leach has been at the company, he has led teams responsible for developing multiple generations of CGMs, including the current-generation G6. Earlier this year, Leach spoke to Drug Delivery Business News about the next-generation Dexcom G7 and other offerings.

Leach’s new role will hold end-to-end responsibility for product at the company. According to a news release, he will drive day-to-day decision-making and resource allocation across all product-facing groups.

Additonally, Leach’s responsibilities include overseeing executive leadership functions. That includes global operations, research and development, quality management and regulatory.

“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” said Kevin Sayer, chair, president and CEO. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”

Quentin Blackford, who was Dexcom’s COO for more than four years, left in fall 2021 to become CEO of iRhythm.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel Tagged With: Dexcom, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS